Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 21;11(3):e005756.
doi: 10.1136/rmdopen-2025-005756.

Persistent-relapsing SARS-CoV-2 infection following rituximab treatment for autoimmune rheumatic diseases: diagnosis and outcomes

Katerina Chavatza  1 , Elisavet Mastrostamati #  2 , Charalampos Charalampidis #  2 , Elvira-Markela Antonogiannaki #  3 , Ioannis Grigoropoulos  2 , Emmanouil Karofylakis  2 , Foteini Gkolemi  2 , Georgios Koromvokis  2 , Electra Kalara  2 , Eleni Sambatakaki  1 , Antonis Fanouriakis #  4 , Konstantinos Thomas #  2
Affiliations

Persistent-relapsing SARS-CoV-2 infection following rituximab treatment for autoimmune rheumatic diseases: diagnosis and outcomes

Katerina Chavatza et al. RMD Open. .

Abstract

Background: COVID-19 may persist or relapse in patients on B-cell depleting biologic therapies.

Objective: To examine the rate and outcome of persistent-relapsing COVID-19 (prCOVID-19) in patients with autoimmune rheumatic diseases (AIRD) treated with rituximab (RTX).

Methods: Single-centre, retrospective cohort study of patients diagnosed with prCOVID-19 (June 2021 to January 2025). prCOVID-19 was defined as persistence of symptoms and lung imaging findings for >30 days, along with persistently positive or PCR-based conversion in upper or lower respiratory tract samples.

Results: 26 out of 225 (11.6%) AIRD patients, previously diagnosed with COVID-19 during RTX treatment period, developed 27 prCOVID-19 events (females: 20 (76.9%), median age: 61 years, median disease duration: 5.5 years, ≥3 COVID-19 vaccine doses: 20 (76.9%)). No prCOVID-19 infection in a control sample of 661 patients treated with other biologic/targeted synthetic/conventional synthetic disease-modifying antirheumatic drugs was documented. Median cumulative RTX dose was 12 g, while in 17 (68%) prCOVID-19 events, IgG levels were below 700 mg/L. Median duration of prCOVID-19 infection was 65 (IQR 74) days and median duration of hospitalisation 10.5 (IQR 14) days. 11 patients (42.3%) had ≥2 hospitalisations, 3 patients needed mechanical ventilation and 4 deaths were recorded. 59 of 113 (52.2%) nasopharyngeal PCR samples (NPS) and 12/17 (70.6%) bronchoalveolar lavage (BAL) PCR samples were positive during prCOVID-19. Bronchoscopy established the diagnosis of prCOVID-19 in 33% of events.

Conclusion: AIRD patients treated with RTX are at risk for prCOVID-19. In such patients, the diagnostic accuracy of NPS PCR is suboptimal, necessitating PCR testing in BAL when prCOVID-19 is highly suspected.

Keywords: COVID-19; Infections; Rituximab.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1. Swimmer plot of disease course. Deaths are denoted with an ‘x’. BAL, bronchoalveolar lavage; NPS, nasopharyngeal; prCOVID-19, persistent or relapsing COVID-19.
See this image and copyright information in PMC

References

    1. Pander J, Termorshuizen F, de Lange DW, et al. The Impact of the COVID-19 Omicron Variant on Immunocompromised Patients: ICU Admissions and Increased Mortality. Infect Dis Ther. 2025;14:881–8. doi: 10.1007/s40121-025-01122-5. - DOI - PMC - PubMed
    1. Hedberg P, Parczewski M, Serwin K, et al. In-hospital mortality during the wild-type, alpha, delta, and omicron SARS-CoV-2 waves: a multinational cohort study in the EuCARE project. Lancet Reg Health Eur. 2024;38:100855. doi: 10.1016/j.lanepe.2024.100855. - DOI - PMC - PubMed
    1. Avouac J, Drumez E, Hachulla E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol . 2021;3:e419–26. doi: 10.1016/S2665-9913(21)00059-X. - DOI - PMC - PubMed
    1. Sormani MP, De Rossi N, Schiavetti I, et al. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol. 2021;89:780–9. doi: 10.1002/ana.26028. - DOI - PMC - PubMed
    1. Choi B, Choudhary MC, Regan J, et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med. 2020;383:2291–3. doi: 10.1056/NEJMc2031364. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources